{"meta":{"query_hash":"dde01f483907","filters":{"venue":"Bayer AG"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/dde01f483907","api":"https://metacan.xera.ac/api/v1/cohort?venue=Bayer+AG"},"results":[{"id":"W6921322643","doi":"10.71943/bayer.figshare.29481581","title":"Publication: Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause - OASIS 1 and 2 Randomized Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Bayer AG","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vasomotor; Placebo; Menopause; Randomized controlled trial; Quality of life (healthcare); Hot flash; Clinical trial","score_opus":0.10196213826273677,"score_gpt":0.43349541182190693,"score_spread":0.33153327355917017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921322643","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1425811,0.50567883,0.007438137,0.053352464,0.050562788,0.124981694,0.040726822,0.0012707512,0.073407345],"genre_scores_gemma":[0.49399343,0.19046754,0.018871285,0.072946295,0.02362185,0.12249211,0.018490396,0.00031095228,0.05880611],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696034,0.0016443891,0.00057363766,0.0002344941,0.00043257268,0.00015444904],"domain_scores_gemma":[0.9938168,0.002580706,0.0020624166,0.00024174133,0.00085754786,0.00044090778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007911576,0.0011862834,0.0021459707,0.000640948,0.00065311615,0.0019480722,0.0008331581,0.0034719806,0.048225336],"category_scores_gemma":[0.015164261,0.0005610211,0.0026625404,0.00088933104,0.0005323341,0.0011507439,0.00041980777,0.0024377191,0.004095434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5872143,0.0029406177,0.002097398,0.110215686,0.012899213,0.00022886913,0.000093803,0.00032978406,0.0034124807,0.0017901636,0.12677726,0.15200041],"study_design_scores_gemma":[0.9209579,0.010657531,0.005379823,0.009096872,0.005274955,0.00012163067,0.00003269807,0.00033619642,0.0007446271,0.00094543706,0.0464156,0.00003678812],"about_ca_topic_score_codex":0.00081837253,"about_ca_topic_score_gemma":0.0021386682,"teacher_disagreement_score":0.048225336,"about_ca_system_score_codex":0.0009853505,"about_ca_system_score_gemma":0.0018230764,"threshold_uncertainty_score":0.16132987},"labels":[],"label_agreement":null}]}